Glumetza Antitrust Settlement

Settlement Structure: Claims Made

Active: Closed

Closed Settlement Statement:

According to court documents, the claim submission deadline has passed. Please contact the claims administrator if you have any questions.

Case Summary:

This settlement resolves an antitrust class action against a number of companies or groups of companies, including Bausch Health Companies, Inc., Salix Pharmaceuticals, Ltd., Depomed, Inc., and Assertio Therapeutics, Inc. The complaint alleged that the companies conspired to delay and impede the entry to the market of less expensive, generic versions of Glumetza, with Lupin agreeing to delay the launch of a generic version in exchange for payment from Bausch and Assertio. Because of that, the complaint alleged, consumers had to pay more for the medicine than they would have had to pay for generic versions.

Docket Number:

3:19-cv- 05822-WHA

Company: Bausch Health Compaines Inc.

Filing Deadline: May 29, 2022

Class Period: May 6, 2012 to August 20, 2020

Objection Deadline: December 22, 2021

Exclusion Deadline: November 19, 2021

Final Approval Hearing: January 20, 2022

Proof of Purchase:

If the court approves the settlement, you will receive an individualized, prepopulated claim form to request your share of the settlement. You will be asked to verify the form’s accuracy and to return it according to directions. If it is not accurate, you will need to provide your own records or other data to correct the information.


You may be eligible if you are a person or entities in the US or its territories who directly purchased Glumetza or generic Glumetza from one of the defendants in this case between May 6, 2012 and August 15, 2020.

Typical Settlement Amount:

Each class member’s share of the net settlement fund will be based on that class member’s qualifying purchases of brand or generic Glumetza according to the Allocation Plan. Class counsel estimates a per-milligram recovery of approximately $0.0044, or $4.40 for 1000 mg tablet and $2.20 per 500 mg tablet. Final amounts will depend on a number of factors, including additional data received, number of opt-outs, and amount of attorneys’ fees and expenses.

Total Settlement Amount: Bausch companies: $300 million; Lupin companies $150 million; Assertio $3.85 million

Class Representative Proposed Incentive Fee:


Law Firms:
Hagens Berman
Hilliard & Shadowen LLP
Sperling & Slater PC

Case Name:

Settlement Website: Glumetza Antitrust Settlement Website

Claims Administrator:
Angeion Group

Claims Administrator Contact Information:

Glumetza Antitrust Litigation
Settlement Administrator
1650 Arch St., Suite 2210
Philadelphia, PA 19103

Tags: Antitrust, Keeping Generics Off the Market, Requiring Consumer to Pay Higher Prices